Changing the Course of Cancer Treatment
AdvanCell is a vertically integrated, clinical stage radiopharmaceutical company developing novel targeted alpha therapies to improve survival and the quality of life for patients with cancer
.webp)
Play Video
829665046
Development Pipeline
AdvanCell is developing a portfolio of Targeted Alpha Therapies for the treatment of cancer including: prostate, skin, pancreatic, breast, bladder, colorectal, kidney, lung, and ovary.
Groundbreaking Technology
THERAPIES
Proprietary ²¹²Pb production technology provides access to an unmatched supply of alpha isotopes to accelerate clinical development of a portfolio of targeted alpha therapies.
Read more
.webp)
ALPHA 212 SUPPLY
Alpha 212 is the product of AdvanCell’s ²¹²Pb generator. It is a quality-controlled dose of ²¹²Pb as an Active Pharmaceutical Ingredient (API) manufactured to international GMP standards.
Read more
.svg)
